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Abstract 
Raynaud’s phenomenon (RP) is the commonest manifestation of systemic sclerosis (SSc) and a major 
cause of disease-related morbidity. This review provides a detailed appraisal of the patient experience of 
SSc-RP and potential implications for disease classification, patient-reported outcome (PRO) instrument 
development and SSc-RP clinical trial design. The review explores the clinical features of SSc-RP, the 
severity and burden of SSc-RP symptoms and the impact of SSc-RP on function, work and social 
participation, body image dissatisfaction and health-related quality of life in SSc. Where management of 
SSc-RP is concerned, the review focuses on the “patient experience” of interventions for SSc-RP, 
examining geographic variation in clinical practice and potential barriers to the adoption of treatment 
recommendations concerning best-practice management of SSc-RP. Knowledge gaps are highlighted that 
could form the focus of future research. A more thorough understanding of the patient experience could 
support the development of novel PRO instruments for assessing SSc-RP. 
Key words: Systemic sclerosis, Raynaud’s phenomenon, Patient experience, Health-related Quality of 
Life, Disability, Function, Impact 
 
Key messages 
1) RP is the commonest and typically earliest clinical manifestation of SSc. 
2) SSc-RP causes distressing physical symptoms, impaired function, body-image dissatisfaction and 
reduced health-related quality of life. 
3) Patient-reported outcome measures that more fully capture the patient experience of SSc-RP are 
needed. 
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Introduction  
Raynaud’s phenomenon (RP) is the commonest manifestation of systemic sclerosis (SSc), affecting 
approximately 96% of patients (1). SSc-RP is also typically the earliest clinical manifestation of SSc, with 
a lag period that can last several years before additional organ-specific disease manifestations emerge (1, 
2). Many comprehensive and valuable reviews have been prepared on the subject of SSc-RP, the majority 
of which have focused on current advances in elucidating the pathogenesis of SSc-RP and evidence-
based approaches to management. A broad definition of RP (episodic digital ischaemia, characterised by 
pain, numbness and digital colour changes, and provoked by cold exposure and/or emotional stress) is 
typically recited, alongside reference to the “significant morbidity” associated with SSc-RP. This review 
provides a more detailed appraisal of the patient experience of SSc-RP and potential implications for 
disease classification, patient-reported outcome (PRO) instrument development and SSc-RP clinical trial 
design. The focus and scope of the review was not amenable to systematic review methods but individual 
comprehensive literature searches (including detailed grey searches of cited papers) were undertaken for 
each of the sub-headings applied to ensure a comprehensive appraisal of the patient experience of SSc-
RP was achieved using a diverse range of sources that included cross-sectional studies, observational 
studies, registry analyses and clinical trial data. References to primary RP, when applied, are primarily 
used to compare and contrast the patient experience of primary RP with that of SSc-RP, or where evidence 
for SSc-RP is lacking. Where management of SSc-RP is concerned, this review focuses on the “patient 
experience” of interventions for SSc-RP, examining geographic variation in clinical practice and potential 
barriers to the adoption of treatment recommendations. Where applicable, knowledge gaps are highlighted 
that could form the focus of future research.  
 
Sensory symptoms of SSc-RP 
Population-based studies of RP (mainly primary) have identified numbness of the fingers as the subjective 
symptom most commonly associated with RP attacks (93.7%), with a lower rate of tingling (53.2%) and 
comparatively low levels of pain (27.6%) (3). In contrast, pain appears to be the predominant symptom 
associated with SSc-RP, perhaps reflecting a greater degree of tissue ischaemia in SSc compared to 
primary RP (4). Median pain visual analogue scores (VAS) are higher in SSc-RP compared to suspected 
connective tissue diseases (CTD)-RP and primary RP (4). Importantly, the same study reported lower 
overall RP “severity” scores in SSc compared to suspected CTD-RP, possibly indicating some degree of 
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habituation to peripheral vascular symptoms in SSc, and also highlighting the impact of item wording on 
responses generated for any given conceptual framework (4). More frequent episodes of SSc-RP was one 
of a small number of disease-specific variables (alongside digital ulcers, gastrointestinal symptoms and 
synovitis) that was independently associated with increased pain (assessed using an 11-point numerical 
rating scale) in SSc (5). Moreover, pain VAS scores aligned with SSc-RP activity scores during factor 
analysis of data obtained from a large clinical trial of SSc-RP, indicating they have strong inter-correlations 
and are measuring conceptually similar aspects of disease activity (6). In addition to pain, a number of 
additional sensory symptoms that might be attributable to SSc-RP have emerged from previous qualitative 
research examining the patient experience in SSc (mainly focussing on quality of life and function) including 
impaired touch function, numbness, sensations related to skin, increased sensibility, loss of sensory 
functions, and reduced tactile sensations in the fingers (7-9). The physical symptoms of SSc-RP are 
important to patients with SSc, with RP and difficulties experienced in cold weather listed as 2 of the 3 
most frequently stated physical symptoms present in SSc (10). No qualitative research studies to date 
have exclusively explored the patient experience of SSc-RP. Little is known about the evolution of sensory 
symptoms of SSc-RP with disease progression. 
 
Digital colour changes of SSc-RP 
Maurice Raynaud provided the first detailed description of the digital colour changes that accompany 
impaired digital perfusion in the phenomenon to which he is eponymously linked (11). Digital pallor 
(ischaemic blanching secondary to vasoconstriction of the pre-capillary arterioles), cyanosis 
(deoxygenation of sequestered blood following constriction of the post-capillary venules) and rubor (a post-
ischaemic reactive hyperaemic phenomenon) comprise the “tri-phasic” digital colour change response that 
might occur during RP attacks as they develop and abate (Figure 1). In practice, tri-phasic colour changes 
are not typical in RP, and certainly not essential for diagnosis. A large community-based questionnaire 
study, estimated the overall prevalence of RP (based on cold sensitivity with white and/or blue digital colour 
changes) at 4.6%, however insistence on a tri-phasic digital colour response would have seen the 
prevalence fall to ~0.1% (12). Population-based assessment of digital colour changes have identified ‘uni-
phasic blanching’, ‘bi-phasic blanching with cyanosis’ and ‘bi-phasic blanching with rubor’ as the 
commonest combinations of digital colour changes reported across the spectrum of RP (3). The UK 
Scleroderma Study Group proposed a consensus classification approach to RP which was subsequently 
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tested in a small (n=30) cohort of healthy controls, primary and secondary RP (13). The proposed presence 
of repetitive episodes of bi-phasic (unspecified) colour changes in either cold or normal environments has 
subsequently been adopted in proposed classification criteria for RP and SSc (14-16). A recent 
international Delphi exercise of SSc-RP experts (n=12), meanwhile, specified the presence of ‘biphasic 
blanching and cyanosis’ of the digits to diagnose RP (17).  
 
Few studies have specifically reported the digital colour changes associated with SSc-RP compared with 
other forms of RP. It has been suggested that cyanosis without blanching is more common in patients with 
SSc-RP than primary forms of RP (18). Reactive hyperaemia, meanwhile, appears to be less common in 
SSc-RP than in primary RP, and may reflect an irreversible obliterative microangiopathy incapable of post-
occlusive vasodilation (19). A recent small study (n=20) identified uni-phasic digital colour changes 
(blanching in 91%, cyanosis in 9%) in over half (55%) of patients with SSc which has implications for our 
current approach to disease classification (4). There was, however, a higher rate of tri-phasic RP symptoms 
in SSc in comparison with primary RP (20% vs 5.1%) (4). The impact of strict adherence on bi-phasic 
digital colour changes on disease classification in early SSc and estimates of prevalence of SSc-RP has 
not previously been explored. The clinical correlates of specific digital colour changes, and combinations 
thereof, in SSc (such as associations with SSc-RP severity, disease duration and presence of digital ulcer 
(DU) disease) is unknown but might provide a readily assessed, and hitherto unused, tool for assessing 
peripheral vascular risk in SSc. For example, digital cyanosis has been shown to correlate with the 
presence of giant capillaries and microhaemorrhages on nailfold capillaroscopy in one study (4).The 
clinical features present within a small group of patients negative for both anti-nuclear antibodies and SSc-
RP from the EUSTAR registry raised the possibility of alternative pathology and the absence of RP 
symptoms should prompt further diagnostic inquiry to exclude sclerosing skin conditions that can mimic 
SSc (20). Gender-specific differences in digital colour changes of RP have not been explored in SSc. 
Population-based studies of primary RP symptoms suggest uni-phasic blanching is commoner in females 
(75% vs. 58%) whereas bi-phasic blanching with rubor is commoner in males (29% vs. 10%) (3).  
 
Body areas affected 
The fingers are the most commonly affected body area in RP and symptoms are bilateral in 90% of patients 
(4). Asymmetry can be a predictor of secondary RP (21). Relative sparing of the thumbs occurs across all 
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forms of RP (4, 22), although the extent of thumb involvement assessed using thermal imaging appears to 
be more exaggerated in secondary RP compared with primary RP (23). Symptoms affecting the earlobes 
and nose, meanwhile, appear to be more common in primary RP (19). 
 
Precipitating and aggravating factors 
Typical descriptions of RP, describe episodic vasospasm occurring in response to cold exposure and/or 
emotional stress. Cold appears to be the more important precipitating event in SSc-RP. A questionnaire-
based study of SSc-RP, reported cold being a precipitating factor in all participants (n=18) whereas only 
1/3 also reported attacks provoked by emotion (24).  These findings were replicated in a recent larger 
survey of a mixed population of RP (n=443) that reported cold exposure as the trigger for RP attacks in 
91% of subjects overall (95% in secondary RP) and emotional stress in 30% (25). Changes in ambient 
temperature were an associated event in 87% of SSc-RP attacks in an early physiological study that 
incorporated ambulatory temperature measurement; compared with only 65.9% of attacks in primary RP 
where a higher proportion of attacks appeared to have been precipitated by emotional stress (26). It was 
also noted that patients with primary RP reporting higher stress ratings prior to RP attacks often had higher 
digital skin temperatures throughout RP attacks (26). The apparent relationship between pre-RP attack 
stress and skin temperature during RP attacks that was not replicated in SSc (26). Physiological studies 
have also identified an increase in physiological markers of stress (such as muscle tension and tachcardia) 
during SSc-RP attacks that is not observed in primary RP attacks (26). In this regard, emotional stress 
might propagate rather than precipitate attacks of SSc-RP. Thematically relevant emotional stressors might 
specifically aggravate RP. For example, imagination of the threat of cold exposure (subjects were asked 
to imagine loss of gloves and car keys during a snowstorm) has been shown to induce reduced finger 
temperature in RP patients but not healthy controls (27). Differences in precipitating events of attacks in 
primary RP and SSc-RP might explain disparity in responses to behavioural intervention for RP. For 
example, finger temperature biofeedback intervention (patients trained to augment the temperature of the 
fingers using a sinusoidal tone that varied according to finger temperature) resulted in reductions in RP 
attack frequency in primary RP but no such response to biofeedback intervention was observed in SSc 
(28).  
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Tobacco use has implications for peripheral vascular complications of SSc. Smokers with SSc are also 3-
4 times more likely to require surgical or pharmacological intervention for digital ischaemia than non-
smokers (29). The relationship between smoking and peripheral vascular compromise appears to extend 
to RP severity. Use of the Comprehensive Smoking Index identified a significant association between 
smoking intensity (packs/day) and SSc-RP severity but the effects dissipated within 1 year of smoking 
cessation; highlighting the importance of this non-pharmacological intervention in SSc-RP (30). 
 
Frequency of RP attacks 
Analysis of clinical trial data provides some insight into the average daily frequency of RP attacks 
experienced (or at least captured using diary monitoring) by patients with SSc; although trials are often 
enriched with patients with more severe SSc-RP (e.g. eligibility criteria mandating exceeded thresholds for 
mean daily average RP attack frequency prior to randomisation) which means the data might be less 
applicable to real-life (31-33). Some studies have also incorporated the presence of digital ulcers as an 
inclusion criteria for study entry into SSc-RP trials (34). For example, diary returns from  RCTs of SSc 
undertaken during the Winter months and/or requiring a minimum of >4-8 RP attacks per week prior to 
enrolment have reported mean daily frequency of RP attacks of between 3.3 and 4.1 attacks/day (6, 31, 
32, 35, 36), or approximately 28 attacks per week (34). Studies of mixed populations of primary and 
secondary RP, sometimes applying similar approaches have revealed a slightly lower mean daily attack 
frequency of 1.9-2.8 attacks/day (37, 38). In contrast, a cross sectional study of SSc that enrolled patients 
with SSc throughout the year and did not require a minimum threshold number of RP attacks prior to 
enrolment, meanwhile, revealed a lower mean daily number of attacks of only 2/day (39). Unsurprisingly, 
seasonal variation in weather influences attack burden in SSc-RP. A small (n=18) longitudinal study 
identified doubling in the daily frequency of RP attacks (2.9 vs. 1.5 attacks/day) during Winter compared 
to Summer despite similar rates of outdoor exposure across seasons (24). This study also highlighted the 
persistent nature of SSc-RP with only 16.7% of respondents reporting no attacks during assessment in the 
Summer (24). Seasonal variation in weather and temperature fluctuations induced by air-conditioning have 
emerged as contributing to SSc-RP symptom burden in qualitative research (40, 41). The relationship 
between RP attack frequency and Raynaud’s classification has varied between studies; with individual 
papers reporting higher, similar and lower RP attack frequency in primary RP compared to secondary RP 
(26, 39, 42). Gender may influence frequency of RP attacks with significantly fewer RP attacks reported in 
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males in one study of primary RP and SSc (39). The frequency of RP attacks does not appear to be higher 
in patients with DU (6). Diary monitoring of SSc-RP symptoms is laborious for patients and SSc-experts 
have expressed concerns regarding the respondent burden and value of this approach (43).  
 
Duration of RP attacks 
The duration of RP attacks over a 2-week RCS diary collection has been relatively consistent across 
studies with studies reporting mean daily aggregate duration spent in RP attacks of between 37-95 
minutes/day, equating to average attack duration of ~15-20 minutes per attack (6, 31, 32, 44). Seasonal 
variation is again relevant with a lower mean daily duration of attacks of ~20 minutes daily in a study whose 
enrolment spanned Winter and Summer (36). The aforementioned longitudinal study examining the impact 
of seasonal variation on SSc-RP symptoms identified an approximate doubling in the aggregate daily 
duration (70 vs. 35 minutes/day) of attacks during Winter compared to Summer, despite similar rates of 
outdoor exposure (24). The duration of RP attacks does not appear to be higher in patients with active DU 
(6). Diary methods of assessing the frequency and duration of SSc-RP assume a paradigm of episodic RP 
attacks and preclude adequate capture of a phenomenon familiar to SSc clinicians and previously 
described by Jill Belch as “what is for many patients the worst feature of the disease - continual digital 
ischaemia” (45). The phrase “my constant companion” was used by a patient to describe SSc-RP in one 
qualitative research study to allude to the persistent threat and/or presence of digital ischaemic symptoms 
experienced by many patients with SSc (8). 
 
Ability to prevent and manage RP attacks 
Management of RP usually includes advice on the use of gloves and hand warmers but evidence 
examining the adoption and efficacy of such self-management approaches in preventing/shortening RP 
attacks is lacking. Measures to avoid or ameliorate SSc-RP attacks might influence diary returns 
concerning RP attack frequency and duration, which might have implications for the value of such 
parameters as clinical trial endpoints. Approximately 2/3 of patients with secondary RP report the ability to 
predict the occurrence of at least half of their RP attacks, with a similar proportion being able to predict 
attack severity based on environmental factors surrounding an attack (25). Nonetheless, the majority of 
patients with secondary RP report difficulty preventing or controlling the occurrence of RP attacks (25). 
This might indicate preventative therapeutic approaches might be preferable to treatment strategies 
The Patient Experience of SSc-RP  9 
designed to ameliorate an attack when it occurs e.g. application of topical vasodilating gels that have been 
the subject of clinical trials for SSc-RP (37). The use of gloves and hard warming devices are considered 
helpful but it has been noted that no intervention prevents all attacks, and barriers to wearing gloves such 
as sclerodactyly and dressings have been identified (8).   
 
The severity of SSc-RP 
Raynaud’s severity is a broad and challenging concept to measure and attempts to achieve this in the 
clinical trial setting have relied upon patient-reported outcome (PRO) instruments such as the RP VAS 
global assessment (focus on difficulty with Raynaud’s), the Raynaud’s severity scale (RSS) and the 
Raynaud’s Condition Score (RCS) (Table 1). The RSS and RCS are single-item scales that ask patients 
to consider the difficulty patients have had because of their SSc-RP, considering the frequency and 
duration of attacks, pain, numbness and impact of SSc-RP on function when considering their score. It is 
not known which domains have the greatest influence on patient response and whether different patients 
focus on different domains when choosing their score. Despite differences in item wording and recall period 
(Table 1), mean values of these global assessments are remarkably consistent at around 4.4 on a 0-10 
NRS across a number of studies (generally undertaken in Winter and requiring a minimum number of RP 
attacks during run-in phase) irrespective of the instrument used (RSS ~4.4 (34), RCS (UK) ~4.2 (32), RCS 
(US) 4.3 (6, 31) and an RCS of 46mm when captured using 0-100mm VAS (45). Furthermore, patient and 
physician global assessments of RP produce similar weighting for RP severity (1.37 and 1.36 on 0-3.0 
scale; also equating to ~4.5 on 0-10 NRS) (6, 31). Mean RCS scores of ~2.0 have been obtained from 
studies that enrolled SSc patients throughout the year and have not mandated a minimum threshold of RP 
attacks to be experienced prior to study entry (39). Principal components factor analysis identified strong 
inter-correlation between the RCS score and other patient-reported RP VAS subscales (e.g. the SHAQ RP 
VAS) but not with physician assessment of RP by VAS, which appeared to have stronger inter-correlation 
with reported frequency and duration of RP attacks (6). Furthermore, factor analysis did not identify strong 
inter-correlation between the RCS score and the frequency/duration of RP attacks, suggesting patient 
assessment of the overall severity of RP and the frequency/duration of RP attacks are separable 
conceptually (6). Raynaud’s severity assessed using the RCS was noted to be higher in patients with DU 
(5.03 vs. 4.1), although the wording of the item question in this work specifically asked subjects to include 
symptoms arising from “painful sores” when choosing their score (Table 1) (6). The severity of RP (based 
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on mean baseline RCS) has been shown to be the same in patients whether or not they are receiving 
vasodilator therapy for their RP (~45mm on 100mm VAS) (46) and similar for patients with primary RP and 
SSc (39). Severity of SSc-RP may differ amongst different ethnic groups with one study identifying higher 
severity of SSc-RP in native North-American populations (47). 
 
Impact of SSc-RP on functional capacity 
 
SSc-RP has consistently emerged as the highest-impact disease-specific manifestation of SSc in terms of 
both frequency and impact on ability to carry out everyday activities in patient surveys undertaken in North 
America, Europe and South America (48-50). The strong association between patient-reported 
assessment of RP severity and measures of function such as the Health Assessment Questionnaire (HAQ) 
and Scleroderma Functional Score are cited as evidence of the contribution of SSc-RP to disability; 
particularly concerning domains concerning hand function (6, 51). The impact of RP on functional capacity 
appears to be greatest for secondary RP, with a higher proportion of patients making adjustments to 
activities of daily living to accommodate RP symptoms (87% vs. 71%) compared to primary RP (25). 
Clinical trials of SSc-RP have demonstrated beneficial effects on functional capacity, sometimes in the 
absence of improvement in RCS diary parameters, suggesting functional impairment secondary to SSc-
RP might be responsive to vasodilator therapy (34, 52). The impact of SSc-RP on function is captured with 
the Scleroderma HAQ (SHAQ) RP VAS subscale which enquires about the extent to which SSc-RP 
interferes with activities. Clinical trial data has identified a mean score of 1.15units (on a 0-3 scale), allowing 
some quantification of the impact of SSc-RP on activities of daily living (6, 53). The SHAQ RP VAS is 
higher in SSc patients with digital pitting scars, digital tip ulcers and digital gangrene (6, 53). 
 
Impact of SSc-RP on quality of life 
 
A large patient survey ranked SSc-RP the highest of the organ-specific manifestations of SSc in terms of 
impact on quality of life and perception of illness severity (54). Quality of life appears to be affected to a 
greater extent by secondary RP than primary RP (6.5 vs. 5.2 on 0-10 NRS) (25). Furthermore, people with 
secondary RP also predict a greater improvement in quality of life when asked to imagine life without RP 
than people with primary RP (25).  
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The psychosocial impact of SSc-RP 
 
No qualitative research studies to date have exclusively explored the patient experience of SSc-RP but 
SSc-RP themes have emerged in studies of SSc exploring quality of life, functioning and body image 
dissatisfaction. The socially isolating and psychological impact of SSc-RP is evident in the following quote 
taken from (55): 
“If it’s 20 degrees below zero outside, you don’t go out at all . . . then I was really depressed, because it 
was so cold for such a long time. I didn’t go out to get my mail from the mail box for almost three weeks.”  
Body image dissatisfaction related to SSc-RP (and the reaction of others) has also emerged in qualitative 
research, as the following quotes attest: 
“What bothers me most? Of course the symptoms of the Raynaud’s syndrome bother me, the fact that 
my hands become blue, the fact that I don’t look at them when I go out in cold weather, the fact that I 
look at the hands of all people. But mostly the psychological issues bother me.” (55) 
“When I’m on public transport and I pay for my bus ticket, when I stretch out my purple hand and the 
seller looks strangely at me, I no longer want to stretch out my hand.” (7) 
The appearance of SSc-RP might have influenced the inclusion of items developed for the Body 
Concealment Scale for Scleroderma such as “I wear gloves to hide my hands”; “I wear make-up to hide 
skin discoloration”; “I avoid shaking hands with people” and “I hide my hands so that people don’t see 
them” and it should not be assumed that body image dissatisfaction pertains solely to the disfiguring effects 
of skin fibrosis and cutaneous ulceration in SSc (56).  
 
SSc-RP is a factor influencing work participation and often requires adapting the work environment and 
wearing adequate clothing to avoid cold exposure (40). Some patients avoid disclosing their SSc diagnosis 
to avoid feeling different to other colleagues, concern about employer reaction and/or possible impact on 
career trajectory (40, 57). Travelling to and from work can represent a barrier to work participation due to 
the distressing effects of cold-exposure e.g. de-icing the car (40).  
 
Barriers to therapeutic intervention 
 
The Patient Experience of SSc-RP  12 
Considering the prevalence and impact of SSc-RP, registry data suggests the range of therapeutic options 
available for the management of SSc-RP is not fully exploited in terms of initiation of treatment and optimal 
therapeutic dosing (58). There is marked variation in the “patient experience” of therapeutic intervention 
for SSc-RP which relates to a number of factors. Physician attitudes to therapeutic intervention might be 
relevant with one survey reporting 20% of scleroderma experts considering less than half of their patients 
requiring treatment for their SSc-RP (59). Such attitudes might offer an explanation for wide variation in 
prescribing practices for SSc-RP (60). Calcium channel blockers (CCBs) are generally considered first-
line therapy for SSc-RP (59, 61) and yet registry analyses suggest only 47-60.9% of patients with SSc ever 
receive CCB therapy for SSc-RP (62, 63). Vasoactive drug use varies according to disease-specific organ 
manifestations and is higher in patients with pulmonary arterial hypertension (84.7%) and digital ulcer 
disease (76.4%), than in patients with SSc-RP alone (58.1%); possibly reflecting physician attitudes to the 
relative importance of therapeutic intervention for SSc-RP (63). Marketing authorisation approval and 
challenges securing reimbursement has also contributed to marked geographic variation in practice with 
intravenous iloprost use for SSc-RP ranging from 1.3% in North America to 21.1% of patients in Europe 
(62, 63). Patient surveys suggest secondary RP is more readily treated with vasoactive drugs than primary 
RP (64% vs. 33%) but the effectiveness of vasoactive treatment is rated modestly with only 21% of 
secondary RP respondents considering their RP treatment “effective” (25). Smoking doesn’t appear to 
influence vasoactive therapy use for SSc-RP (30). Surveys have identified limited utilisation of validated 
PRO instruments for SSc-RP in clinical practice which has limited the emergence of practice-based 
evidence to ascertain the comparative efficacy of different vasodilator approaches to SSc-RP management 
(43, 58). 
 
Conclusions 
SSc-RP is the commonest disease-specific manifestation of SSc and is associated with considerable 
disease-related morbidity across a broad set of domains including pain, impaired hand function, reduced 
social participation, body image dissatisfaction, increased reliance on others and reduced quality of life. 
There are limitations to the current approaches for assessing SSc-RP. An enhanced understanding of the 
patient experience of SSc-RP might support the development of novel approaches to the assessment of 
SSc-RP that more fully captures the patient experience of SSc-RP and facilitates a more discerning 
appraisal of the efficacy of therapeutic intervention.  
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Figure 1. Acrocyanosis in the digits of a patient with limited cutaneous systemic sclerosis.  
 
In addition to the typical cyanosis of SSc-RP, there is also evidence of active digital ulceration 
affecting the right thumb tip and digital pitting affecting the right 4th digit, left thumb and left 5th digit. 
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Table 1. Existing patient and clinician-reported outcome instruments for assessing SSc-RP 
 
* Sometimes adapted from its original form as a 0-100mm VAS with mean values obtained over 1 
week of assessment 
 
 
 
  
 
Name Study Item metric Recall 
Period 
Score Item Wording 
Patient-Reported Outcomes 
Raynaud’s 
Severity Scale  
Wigley et 
al. 1994 
11-point NRS (0-10) 1 day Mean daily score over 
3-week period 
Patients were asked to consider in their Raynaud severity score the number 
and duration of attacks; symptoms, such as numbness, burning, and pain and 
tingling; hand disability; and influence of cold on daily activity. An attack was 
defined as an episode of pallor followed by cyanosis with or without 
associated pain. 
Raynaud’s 
Condition 
Score 
Black et al. 
1998  
11-point NRS (0-10); 0 
None – 10 very severe 
1 day Mean daily score over 
2-week period*  
Please rate the difficulty you had today with your Raynaud’s condition. Please 
consider the following when choosing your score: The number of Raynaud’s 
attacks; the duration of the attacks; whether you had, for example, 
numbness, burning and tingling, and the effect cold had on your ability to use 
your hands and to perform other activities. 
Raynaud’s 
Condition 
Score 
Wigley et 
al. 1998 
11-point NRS (0-10); 0 
No difficulty -10 
Extreme difficulty* 
1 day Mean daily score over 2-week 
period* 
The Raynaud’s Condition Score is your rating of how much difficulty you had 
with your Raynaud’s TODAY. Consider how many attacks you had and how 
long they lasted. Consider how much pain, numbness, or other symptoms the 
Raynaud’s caused in your fingers (including painful sores) and how much the 
Raynaud’s ALONE affected the use of your hands today.  
Patient Global 
Assessment  
Wigley et 
al. 1998 
0-15cm VAS; (0 no 
disease activity and 100 
very severe)  
7 days 15cm re-scaled to 
continuous 0-3 scale 
to match SHAQ 
In the past week, how severe was your Raynaud’s disease?” 
 
SHAQ RP VAS 
Subscale 
Steen & 
Medsger 
1997 
0-15cm VAS; (0 does 
not interfer and 100 
very severe) 
7 days 15cm re-scaled to 
continuous 0-3 scale 
In the past week how much have your Raynaud’s problems interfered with 
your activities?  
Clinician-Reported Outcomes 
Physician 
Global 
Assessment 
Wigley et 
al.1994 
4-point NRS (0-3)  7 days  
or 1 day 
Score either on day of 
assessment of taking 
into account last 7 
days 
The study physician evaluated the severity of patients' Raynaud phenomenon 
using a scoring system in which 0 represented no attack, 1 represented a 
mild attack, 2 represented a moderate attack, and 3 represented a severe 
attack 
Physician 
Global 
Assessment  
Wigley et 
al. 1998 
0-15cm VAS; (anchored 
at 0 no disease activity 
and at 100 very severe 
disease activity)   
7 days 15cm re-scaled to 
continuous 0-3 scale 
to match SHAQ 
 “How severe would you rate the patient’s Raynaud’s disease for the past 
week?”  
